Femasys Inc (FEMY)

Femasys Inc. experienced notable insider trading activity on August 7, 2026, when five key executives, including the CEO and CFO, executed purchase orders. These acquisitions represent the most recent recorded transactions for the firm. No further buying or selling by company leadership has occurred within the last three months.
Ticker: FEMY Exchange: NAS


Loading...
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Femasys Inc. Upgrade to see score, net flow, insiders and the full signal context.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Mifek Jeffrey Gerald Chief Clinical-Medical Affairs Officer
Transaction date
Purchase
Price
232.10
Quantity 14,149 +35.2%
Value US$1,827,196
Sipos Jeremy Alexander Chief Technology Officer Officer
Transaction date
Purchase
Price
183.26
Quantity 76,912 +38.6%
Value US$1,994,596
Canning John Charles Chief Operating Officer Officer
Transaction date
Purchase
Price
307.52
Quantity 39,766 -48.5%
Value US$4,575,315
1.8
Elefant Dov Chief Financial Officer Officer
Transaction date
Purchase
Price
3.20
Quantity 15,625 New position
Value US$50,000
Lee-Sepsick Kathy Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.20
Quantity 15,625 New position
Value US$50,000
0.8
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
9.95
Quantity 1,000 +0.9%
Value US$9,950
0.8
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.00
Quantity 40,000 +400.0%
Value US$520,000
Adams John Q JR Non-Executive Director
Transaction date
Purchase
Price
13.00
Quantity 40,000 New position
Value US$520,000
Uzialko Edward R Non-Executive Director
Transaction date
Purchase
Price
13.00
Quantity 100,000 +359.9%
Value US$1,300,000
0.8
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
12.88
Quantity 10,000 New position
Value US$128,800
0.8
Dyett John Non-Executive Director Large shareholder
Transaction date
Purchase
Price
13.18
Quantity 2,500 New position
Value US$32,950
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value
Number of shares Price Value Details
2026-08-11 2026-08-07 B Purchase

Chief Clinical-Medical Affairs

Officer
14,149 +35.2%
232.10
US$1,827,196
14,149 +35.2% 232.10 US$1,827,196
2026-08-11 2026-08-07 B Purchase

Chief Technology Officer

Officer
76,912 +38.6%
183.26
US$1,994,596
76,912 +38.6% 183.26 US$1,994,596
2026-08-11 2026-08-07 B Purchase

Chief Operating Officer

Officer
39,766 -48.5%
307.52
US$4,575,315
39,766 -48.5% 307.52 US$4,575,315
2026-08-11 2026-08-07 B Purchase

Chief Financial Officer

Officer
15,625 New position
3.20
US$50,000
15,625 New position 3.20 US$50,000
2026-08-11 2026-08-07 B Purchase

Chief Executive Officer

Executive Director
15,625 New position
3.20
US$50,000
15,625 New position 3.20 US$50,000
2021-06-24 2021-06-23 B Purchase Non-Executive Director Large shareholder
1,000 +0.9%
9.95
US$9,950
1,000 +0.9% 9.95 US$9,950
2021-06-24 2021-06-22 B Purchase Non-Executive Director Large shareholder
40,000 +400.0%
13.00
US$520,000
40,000 +400.0% 13.00 US$520,000
2021-06-24 2021-06-22 B Purchase Non-Executive Director
40,000 New position
13.00
US$520,000
40,000 New position 13.00 US$520,000
2021-06-24 2021-06-22 B Purchase Non-Executive Director
100,000 +359.9%
13.00
US$1,300,000
100,000 +359.9% 13.00 US$1,300,000
2021-06-24 2021-06-18 B Purchase Non-Executive Director Large shareholder
10,000 New position
12.88
US$128,800
10,000 New position 12.88 US$128,800
2021-06-24 2021-06-18 B Purchase Non-Executive Director Large shareholder
2,500 New position
13.18
US$32,950
2,500 New position 13.18 US$32,950